AtriCure to Announce Third Quarter 2020 Financial Results
AtriCure, a leader in treatments for atrial fibrillation (Afib), announced that it will release its third quarter 2020 financial results on November 5, 2020. A conference call to discuss these results will take place at 4:30 p.m. Eastern Time on the same day. AtriCure's innovative technologies, like the FDA-approved Isolator® Synergy™ Ablation System and the AtriClip® Left Atrial Appendage Exclusion System, are widely utilized by medical professionals for Afib management, affecting over 33 million people globally. For further details, visit AtriCure.com.
- AtriCure is a leading innovator in Afib treatment, indicating strong market positioning.
- The company’s Isolator® Synergy™ Ablation System is FDA-approved for persistent Afib, showcasing its unique product offerings.
- The AtriClip® product line is the most widely sold LAA management device, enhancing revenue potential.
- None.
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2020 financial results on Thursday, November 5, 2020.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 5, 2020 to discuss its third quarter 2020 financial results. The call may be accessed through an operator by calling (844) 884-9951 for domestic callers and (661) 378-9661 for international callers using conference ID number 8584906. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the presentation will be available for 90 days following the presentation.
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
